RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PETRELLI F
Collezione AOU San Luigi di Orbassano

Items : 14

Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis. in Seminars in oncology / Semin Oncol. 2025 Feb;52(1):14-18. doi: 10.1053/j.seminoncol.2024.11.001. Epub 2024 Dec 31.

2025
ASL Città di Torino
ASL Torino 3
AOU San Luigi di Orbassano

Novello S; Maccioni A; Scartozzi M; Dottorini L; Carnio S; Morelli AM; Bertaglia V; Nepote A; Solinas C; Petrelli F;

Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study). in Scientific reports / Sci Rep. 2023 Jan 23;13(1):1257. doi: 10.1038/s41598-023-28464-9.

2023
AOU San Luigi di Orbassano

Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E;

Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. in Cytokine & growth factor reviews / Cytokine Growth Factor Rev. 2022 Oct;67:1-10. doi: 10.1016/j.cytogfr.2022.07.009. Epub 2022 Jul 30.

2022
AOU San Luigi di Orbassano

Bertaglia V; Petrelli F; Porcu M; Saba L; Pearce J; Luciani A; Solinas C; Scartozzi M;

Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. in International journal of cancer / Int J Cancer. 2022 Nov 15;151(10):1760-1769. doi: 10.1002/ijc.34156. Epub 2022 Jun 23.

2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Morano F; Pietrantonio F; Di Maio M; Di Bartolomeo M; Rossi A; Giordano M; Antonuzzo L; Petrelli F; Ratti M; Berenato R; Clavarezza M; Zaniboni A; Murialdo R; Tampellini M; Fanchini L; Antoniotti C; Bozzarelli S; Sartore-Bianchi A; Lonardi S; Pagani F; Randon G; Prisciandaro M; Raimondi A;

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. in BMC cancer / BMC Cancer. 2022 Aug 24;22(1):915. doi: 10.1186/s12885-022-10018-3.

2022
AOU San Luigi di Orbassano

Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. in The oncologist / Oncologist. 2021 Oct;26(10):e1854-e1861. doi: 10.1002/onco.13851. Epub 2021 Jun 18.

2021
AOU San Luigi di Orbassano

Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis. in Endocrine-related cancer / Endocr Relat Cancer. 2021 Jul 5;28(8):593-604. doi: 10.1530/ERC-21-0123.

2021
AOU San Luigi di Orbassano

Gurizzan C; Zamparini M; Volante M; Tovazzi V; Amoroso V; Consoli F; Petrelli F; Grisanti S; Bossi P; Berruti A;

Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2021 Jul;29(7):3971-3980. doi: 10.1007/s00520-020-05972-2. Epub 2021 Jan 3.

2021
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

de Braud F; Di Bartolomeo M; Pietrantonio F; Randon G; Prisciandaro M; Ambrosini M; Pagani F; Niger M; Antista M; Longarini R; Cinieri S; Giordano M; Antonuzzo L; Petrelli F; Toscano G; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Racca P; Amatu A; Rimassa L; Antoniotti C; Morano F; Lonardi S; Corallo S; Raimondi A;

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.

2020
AOU San Luigi di Orbassano

Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; et alii...

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Aug;135:230-239. doi: 10.1016/j.ejca.2020.04.048. Epub 2020 Jul 2.

2020
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Pietrantonio F; Di Bartolomeo M; Peverelli G; de Braud F; Antista M; Niger M; Bergamo F; Cinieri S; Longarini R; Giordano M; Antonuzzo L; Petrelli F; Adamo V; Tomasello G; Zaniboni A; Clavarezza M; Murialdo R; Tampellini M; Ritorto G; Sartore-Bianchi A; Rimassa L; Antoniotti C; Corallo S; Lonardi S; Morano F; Raimondi A; Di Maio M; Raimondi A; Di Maio M; et alii...

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. in JAMA oncology / JAMA Oncol. 2019 Sep 1;5(9):1268-1275. doi: 10.1001/jamaoncol.2019.1467.

2019
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Longarini R; Petrelli F; Giordano M; Tomasello G; Adamo V; Zaniboni A; Murialdo R; Smiroldo V; Niger M; Antista M; Caporale M; Berenato R; Clavarezza M; Racca P; Tampellini M; Sartore-Bianchi A; Bergamo F; Rimassa L; Cremolini C; Raimondi A; Lonardi S; Miceli R; Corallo S; Pietrantonio F; Morano F; Cinieri S; Falcone A; Zagonel V; Di Bartolomeo M; et alii...

BRAF-mutated metastatic colorectal cancer between past and future. in British journal of cancer / Br J Cancer. 2015 Dec 1;113(11):1634-5. doi: 10.1038/bjc.2015.316. Epub 2015 Sep 10.

2015
AOU San Luigi di Orbassano

Cremolini C; Di Maio M; Petrelli F; Berenato R; Loupakis F; Pietrantonio F;

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13.

2014
AOU San Luigi di Orbassano

Gregorc V; Novello S; Lazzari C; Barni S; Aieta M; Mencoboni M; Grossi F; De Pas T; de Marinis F; Bearz A; Floriani I; Torri V; Bulotta A; Cattaneo A; Grigorieva J; Tsypin M; Roder J; Doglioni C; Levra MG; Petrelli F; Foti S; Viganò M; Bachi A; Roder H;

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2012 Aug;23(8):2072-2077. doi: 10.1093/annonc/mdr572. Epub 2012 Jan 4.

2012
AOU San Luigi di Orbassano

Santini D; Tampellini M; Vincenzi B; Ibrahim T; Ortega C; Virzi V; Silvestris N; Berardi R; Masini C; Calipari N; Ottaviani D; Catalano V; Badalamenti G; Giannicola R; Fabbri F; Venditti O; Fratto ME; Mazzara C; Latiano TP; Bertolini F; Petrelli F; Ottone A; Caroti C; Salvatore L; Falcone A; Giordani P; Addeo R; Aglietta M; Cascinu S; et alii...